Abstract
Cisplatin (CisPt) is an effective chemotherapeutic agent against several human cancers, but it produces important nephrotoxicity, leukopenia, and mortality. In this work, we report initial results on the potential ability of diallyl disulfide (DADS) to block these toxicities without compromising chemotherapy. Male Sprague Dawley rats were used (control, DADS, CisPt, and CisPt/DADS). CisPt was administered sc as a single dose (10.5 mg/kg) in saline. DADS was given daily intragastrically in olive oil (292.5 mg/kg) 1 h before CisPt administration the first day and 146.25 mg/kg during the next 3 days. The animals were sacrificed at the fifth day after CisPt administration. DADS significantly decreased CisPt-induced nephrotoxicity as evaluated by histology and by seric urea (CisPt: 11.05 ± 3.59; CisPt/DADS: 6.53 ± 1.74) and creatinine (CisPt: 24.74 ± 3.03; CisPt/DADS: 14.83 ± 2.07). DADS also decreased leukopenia (CisPt: 13.5% and CisPt/DADS: 43.4% respect the control), and mortality (CisPt: 50%; CisPt/DADS: 29%). DADS showed ability to interact with reactive oxygen species (H2O2, hydroperoxides, OH•) and with iron. DADS treatment does not change Platinum levels in kidney (CisPt: 15.2 ± 5.1; CisPt/DADS: 13.9 ± 4.5). Because DADS is known to inhibit cellular replication and to promote apoptosis of tumor cells, results suggest that DADS merit to be tested as a potential coadjuvant of CisPt chemotherapy in tumor-bearing animals.
ACKNOWLEDGMENTS
J. P. Chiarandini Fiore has a doctoral fellowship from the National Research Council from Argentina (CONICET).
Notes
a Abbreviation is as follows: DADS, diallyl disulfide. CisPt was administered subcutaneously as a single dose (10.5 mg/kg) in saline. DADS was given daily intragastrically in olive oil (292.5 mg/kg) 1 h before CisPt administration the 1st day and 146.25 mg/kg during the next 3 days. Animals were sacrificed at the 5th day after CisPt. Seric urea and creatinine were determined as described in Materials and Methods. Groups of 8 animals were used. Values are the means ± SD from results obtained in 4 similar experiments.
b P < 0.001. Urea: Control vs. CisPt, DADs vs. CisPt/DADS; Creatinine: Control vs. CisPt, CisPt vs. CisPt/DADS, DADS vs. CisPt/DADS.
c P < 0.05. Urea: CisPt vs. CisPt/DADS; Creatinine: Control vs. DADS.
a Abbreviations are as follows: DADS, diallyl disulfide; CisPt, cisplatin. Rats were treated with CisPt and DADS, and histological grading was performed as discussed in Materials and Methods. Reported results are the mean of the observations made by 2 independent workers in 7 similar experiments.